ACM
IMVT icon

AlphaCrest Capital Management’s Immunovant IMVT Stock Holding History

AlphaCrest Capital Management’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-39,200
Closed -$629K – 1284
2021
Q1 		$629K Buy
+39,200
New +$1.03M 0.04% 694

Other funds holding IMVT

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

AlphaCrest Capital Management's IMVT Position: Q2 2021 in Review

AlphaCrest Capital Management sold out of Immunovant (IMVT) in Q2 2021, closing a stake of 39,200 shares — an estimated $629K sold.

AlphaCrest Capital Management first reported a position in IMVT in Q1 2021 and held it in 1 quarter. The position peaked at $629K in Q1 2021. 110 funds tracked by Wall St. Rank hold IMVT as of Q2 2021.

  • AlphaCrest Capital Management reported no remaining Immunovant position as of Q2 2021 after selling out during the quarter.
  • AlphaCrest Capital Management sold 39,200 Immunovant shares in Q2 2021, an estimated $629K.
  • AlphaCrest Capital Management first reported a position in Immunovant in Q1 2021 and held it in 1 quarter.
  • AlphaCrest Capital Management's Immunovant position peaked at $629K in Q1 2021.
  • 110 funds tracked by Wall St. Rank held Immunovant as of Q2 2021.

Based on AlphaCrest Capital Management's 13F filing for Q2 2021, filed 12 Aug 2021.